sever
lectin
isol
natur
sourc
inhibit
microbi
viral
pathogen
vitro
vivo
griffithsin
grft
deriv
red
alga
griffithsia
sp
homodimer
lectin
total
six
oligosaccharid
bind
site
recogn
termin
oligomannos
residu
asparagin
n
link
structur
interestingli
oligomannos
structur
constitut
vast
major
nlink
glycan
glycan
shield
help
viru
evad
immun
surveil
griffithsin
inhibit
vitro
midpicomolar
rang
nanomolar
activ
sever
envelop
virus
acut
respiratori
syndromecoronaviru
sarscov
japanes
enceph
viru
jev
hepat
c
viru
hcv
herp
simplex
grft
bind
oligosaccharid
multipl
site
singl
molecul
therebi
occlud
function
import
domain
viral
envelop
glycoprotein
prevent
interact
cellsurfac
receptor
imped
structur
transit
indispens
infect
initi
demonstr
grft
may
also
act
inhibit
viru
egress
spread
postinfect
vitro
importantli
grft
antivir
activ
confirm
preexposur
prophylaxi
anim
model
lectin
inhibit
sarscov
jev
hcv
potent
activ
grft
coupl
excel
safeti
profil
shown
vitro
sever
anim
model
taken
togeth
grft
toler
profil
broad
spectrum
activ
suscept
virus
vitro
vivo
advoc
develop
antivir
chemoprev
chemotherapeut
despit
impress
wealth
studi
assess
grft
therapeut
valu
littl
known
pharmacokinet
profil
could
limit
use
drug
therefor
studi
aim
evalu
pharmacokinet
properti
promis
antivir
administr
differ
rout
found
grft
readili
bioavail
rat
intraven
subcutan
treatment
show
distinct
pharmacokinet
profil
accord
rout
employ
howev
grft
detect
serum
oral
singl
chronic
dose
nevertheless
small
fraction
orallyadminist
grft
formul
pb
found
fecal
extract
activ
form
find
indic
grft
pharmacokinet
depend
administr
rout
indic
potenti
multius
lectin
treatment
system
enter
infect
caus
suscept
envelop
virus
recombin
grft
produc
nicotiana
benthamiana
plant
describ
previous
purifi
puriti
phosphatebuff
salin
pb
ph
endotoxin
unit
eu
per
milligram
spragu
dawley
sd
rat
rattu
norvegicu
charl
river
laboratori
usa
weigh
g
hous
temperatur
humiditycontrol
room
altern
lightdark
cycl
h
standard
diet
water
ad
libitum
anim
procedur
approv
univers
louisvil
institut
anim
care
use
committe
sd
rat
g
procur
charl
river
indwel
femor
vein
cathet
week
adapt
anim
weigh
treat
singl
dose
grft
differ
rout
intraven
treatment
indwel
cathet
check
patenc
either
mgkg
grft
infus
cathet
period
subcutan
treatment
mgkg
grft
inject
skin
shoulder
oral
dose
mgkg
grft
formul
pb
final
volum
ml
administ
gavag
approxim
blood
collect
intraven
subcutan
dose
anim
via
indwel
femor
cathet
follow
time
point
grft
administr
min
min
h
h
h
h
h
h
h
h
case
oral
treatment
blood
drawn
min
min
min
h
h
h
h
h
h
postadministr
anim
sacrif
asphyxi
follow
thoracotomi
studi
complet
rat
treat
singl
dose
mgml
grft
either
intraven
n
indwel
cathet
subcutan
n
addit
rat
treat
mgml
grft
ml
solut
gavag
postdosag
anim
place
metabol
cage
urin
sampl
collect
h
fecal
pellet
collect
h
urin
volum
fecal
pellet
mass
record
mass
balanc
calcul
total
rat
indwel
cathet
treat
daili
pb
n
mgkg
grft
n
mgkg
grft
n
period
day
gavag
ml
solut
blood
sampl
drawn
via
later
tail
vein
day
approxim
h
oral
dose
day
anim
sacrif
approxim
h
treatment
asphyxi
follow
thoracotomi
blood
sampl
obtain
cardiac
punctur
urin
sampl
collect
well
select
time
point
oral
dose
six
fecal
pellet
randomli
collect
h
initi
treatment
select
day
thereaft
briefli
ml
pb
ad
per
gram
pellet
min
mix
homogen
clear
twice
centrifug
min
g
result
fecal
suspens
store
determin
grft
concentr
antihiv
activ
fecal
extract
sampl
pool
combin
equal
volum
extract
cage
within
applic
treatment
group
fecal
extract
chronic
treat
anim
underw
addit
process
remov
contamin
pseudoviru
neutral
assay
sampl
steril
filter
use
costar
spinx
centrifug
tube
filter
contain
cellulos
acet
filter
filtrat
sampl
dialyz
kda
molecular
weight
cut
pb
h
extract
mass
balanc
experi
prepar
desicc
rehydr
fecal
pellet
overnight
desicc
pellet
pulver
use
commerci
coffe
grinder
pellet
extract
formul
use
g
dri
powder
ml
pb
result
fecal
slurri
thoroughli
mix
clear
twice
centrifug
g
min
final
supernat
aliquot
grft
concentr
determin
detect
trace
amount
grft
serum
fecal
extract
enzymelink
immunosorb
assay
elisa
carri
previous
describ
coat
plate
purifi
influenza
hemagglutinin
ha
kentucki
bioprocess
owensboro
ky
usa
instead
ngml
method
detect
activ
grft
neutral
activ
assess
pool
fecal
extract
chronic
treat
anim
previous
describ
briefli
envpseudotyp
viru
particl
obtain
transfect
cell
titrat
tzmbl
cell
antivir
effect
reflect
luciferas
report
gene
activ
determin
rel
luminesc
substrat
addit
inhibitori
dose
repres
sampl
dilut
requir
reduc
luminesc
half
comparison
control
well
organ
includ
liver
kidney
heart
lung
spleen
obtain
anim
paraffin
embed
fixat
neutral
buffer
formalin
section
stain
hematoxylin
eosin
h
e
evalu
blind
manner
veterinari
pathologist
dr
mari
proctor
univers
louisvil
gross
cellular
abnorm
pharmacokinet
paramet
obtain
pk
solut
softwar
summitpk
eugen
usa
use
grft
serum
concentr
sampl
time
point
valu
gener
concentr
time
curv
base
upon
grft
amount
administ
includ
absorpt
distribut
elimin
halflif
area
curv
auc
volum
distribut
vd
clearanc
maximum
serum
concentr
cmax
graph
pad
prism
sa
softwar
version
use
statist
analys
p
consid
statist
signific
grft
detect
time
point
assess
administr
singl
dose
figur
shown
figur
serum
concentr
increas
lectin
dose
min
anim
display
averag
serum
grft
concentr
mgkg
group
respect
amount
rapidli
decreas
time
vs
ngml
vs
ngml
vs
ngml
h
postadministr
respect
interestingli
grft
remain
detect
serum
low
concentr
h
posttreat
figur
subcutan
administr
serum
grft
amount
gradual
increas
ngml
min
mgkg
group
respect
peak
approxim
h
postadministr
ngml
respect
figur
follow
decreas
trend
similar
observ
intraven
dose
anim
h
ngml
grft
respect
detect
low
dose
treatment
group
ngml
obtain
drug
administr
mgkg
respect
grft
detect
serum
sampl
treatment
group
h
posttreat
figur
tabl
summar
variou
pharmacokinet
paramet
grft
h
analysi
concentrationtim
curv
pk
solut
softwar
intraven
administr
reveal
multiphas
kinet
three
distinct
phase
absorpt
distribut
elimin
halfliv
absorpt
h
distribut
h
elimin
h
h
h
h
respect
anim
treat
intraven
mgkg
grft
similar
valu
obtain
high
dose
administr
rout
subcutan
administr
mgkg
grft
pharmacokinet
paramet
show
increas
trend
h
h
h
obtain
absorpt
distribut
elimin
halfliv
respect
similar
valu
obtain
high
dose
mgkg
paramet
auc
valu
higher
intraven
administ
anim
subcutan
group
low
vs
high
vs
grft
dose
similar
trend
observ
maximum
serum
concentr
cmax
intraven
administr
mgkg
grft
result
cmax
valu
respect
subcutan
administ
anim
valu
drop
respect
volum
distribut
vd
clearanc
rate
rel
low
rout
dose
test
grft
detect
serum
time
point
oral
administr
mgkg
singl
dose
h
initi
dose
anim
treat
mgkg
grft
display
fecal
grft
concentr
averag
approxim
ngml
figur
howev
level
decreas
group
h
dose
ngml
obtain
averag
mgkg
grft
treatment
group
respect
figur
fecal
pellet
collect
day
day
treatment
fecal
extract
anim
treat
mgkg
grft
show
concentr
rang
ngml
higher
amount
obtain
treatment
mgkg
ngml
figur
fecal
extract
rat
oral
treat
mgkg
grft
neutral
pseudovirus
clade
c
primari
sexual
transmit
isol
dilut
factor
requir
reduc
luminesc
pb
treat
control
valu
respect
day
figur
tabl
interestingli
higher
antivir
activ
obtain
mgkg
dose
day
respect
day
respect
treatment
tabl
figur
concentr
activ
grft
assess
urin
fecal
materi
produc
within
h
follow
singl
intraven
subcutan
oral
treatment
respect
mg
approxim
mgkg
dose
intraven
subcutan
administr
result
grft
urin
respect
figur
meanwhil
urin
grft
level
anim
treat
oral
detect
instead
grft
found
fecal
extract
approxim
grft
recov
fece
data
describ
confirm
previou
find
subcutan
grft
administr
well
toler
laboratori
rodent
speci
mous
guinea
pig
accumul
therapeut
relev
level
addit
work
reveal
complex
pk
profil
grft
rat
standard
rodent
model
use
pk
studi
shown
grft
drug
concentr
time
curv
vari
administr
rout
figur
inde
multiphas
elimin
pattern
observ
intraven
treatment
grft
serum
halflif
chang
time
although
bolu
grft
elimin
within
h
therapeut
effect
amount
remain
least
h
postadministr
complex
elimin
pattern
observ
recombin
protein
base
pharmaceut
show
differ
time
maximum
serum
concentr
elimin
rate
grft
excret
mainli
urin
start
shortli
intraven
dose
urin
concentr
decreas
time
vivo
radiolabel
studi
requir
determin
full
grft
distribut
bodi
addit
degrad
proteolysi
lectin
might
occur
previou
studi
shown
grft
rel
resist
proteas
howev
suscept
leukocyt
elastas
therefor
grft
might
also
vulner
yet
test
proteas
extens
vitro
proteas
degrad
assay
catabolit
assess
serum
system
administr
need
fulli
understand
grft
suscept
proteas
shown
final
phase
grft
elimin
halflif
compar
protein
therapeut
monoclon
antibodi
smaller
molecul
biolog
serum
persist
could
potenti
result
redistribut
deeper
physiolog
compart
howev
like
grft
involv
interact
endogen
protein
hypothes
test
vivo
radiolabel
grft
cellular
protein
bind
experi
subcutan
grft
treatment
result
serum
concentr
peak
approxim
h
postadministr
elimin
pattern
mirror
intraven
treatment
thereaft
figur
initi
distribut
phase
immedi
follow
subcutan
dosag
fairli
compar
grft
dose
mgkg
howev
high
dose
result
markedli
increas
grft
peak
concentr
total
drug
exposur
bioavail
compar
low
dose
reflect
auc
valu
approxim
fourfold
increas
total
drug
amount
obtain
mgkg
dose
could
attribut
gradual
releas
absorpt
inject
site
time
compet
distribut
elimin
degrad
process
occur
lectin
enter
circul
capillari
bed
sinc
serum
grft
concentr
peak
h
post
bolu
dose
persist
h
daili
subcutan
selfadministr
would
maintain
potenti
therapeut
effect
understand
grft
pharmacokinet
critic
futur
studi
given
subcutan
dose
may
viabl
maintain
potenti
therapeut
drug
concentr
follow
paramet
assess
steadyst
drug
concentr
load
dose
mainten
dose
dose
interv
grft
hiv
approxim
pm
base
lh
clearanc
determin
singl
mgkg
subcutan
dose
administr
mgkg
grft
everi
h
would
achiev
steadyst
concentr
nm
time
howev
grft
higher
hcv
nm
sarscov
nm
indic
optim
regimen
determin
variou
viral
diseas
maintain
serum
drug
concentr
therapeut
steadyst
level
avoid
toxic
frequent
regimen
could
also
design
base
data
minim
peak
trough
drug
level
maintain
potenti
effect
steadyst
serum
concentr
instanc
steadi
state
concentr
nm
would
requir
administ
interestingli
grft
amount
dose
subcutan
affect
bioavail
mgkg
respect
grft
display
bioavail
rate
aucsubcutan
aucintraven
although
underli
reason
remain
unclear
find
highlight
impact
dose
select
studi
design
note
activ
grft
detect
studi
preliminari
experi
laboratori
shown
grft
may
bind
protein
plasma
howev
bind
affect
actual
detect
grft
deserv
attent
use
sensit
measur
lectin
eg
mass
spectrometri
perform
treatment
radiolabel
compound
would
provid
addit
insight
experi
carri
futur
studi
contrast
parenter
rout
oral
administr
grft
yield
detect
blood
level
nevertheless
activ
grft
concentr
present
fece
indic
could
use
oral
prevent
rectal
transmiss
pathogen
inde
nonabsorpt
grft
oral
administr
allow
drug
fraction
pass
digest
tract
ultim
expel
fecal
materi
figur
approxim
initi
grft
amount
recov
fece
shield
lectin
stomach
acid
proteas
effect
might
increas
excret
amount
nonetheless
grft
fecal
level
exceed
toward
within
first
h
post
treatment
daili
prophylact
treatment
well
establish
eg
truvada
current
prescrib
high
risk
popul
includ
men
sex
men
msm
addit
antiretrovir
employ
follow
occup
nonoccup
exposur
hiv
therefor
oral
grft
could
util
daili
seed
bowel
rectal
mucosa
potenti
block
hiv
infect
interestingli
grft
passag
follow
oral
dosag
consist
typic
intestin
transit
time
h
final
given
serum
grft
concentr
peak
h
post
bolu
parenter
dose
persist
h
daili
subcutan
selfadministr
would
maintain
potenti
therapeut
effect
prophylact
hiv
continu
worldwid
spread
envelop
virus
sarscov
hcv
demand
robust
prevent
measur
grft
pharmacokinet
profil
support
multipl
potenti
use
enabl
design
differ
regimen
system
postexposur
treatment
subcutan
selfadministr
would
viabl
effect
achiev
potenti
therapeut
serum
concentr
grft
context
postexposur
prophylaxi
emerg
viral
threat
initi
intraven
bolu
treatment
grft
may
use
achiev
speedi
serum
peak
level
addit
grft
could
util
oral
prevent
colorect
transmiss
hiv
suscept
virus
preexposur
prophylact
set
